ARROWHEAD PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $371.33 thousand for the 3-month period ending 2014-06-30, per its 10-Q filed 2014-08-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2014-08-12
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2014-06-30 was $371.33K.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2014-03-31 was $2.80M.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2013-12-31 was $314.86K, a 56733.57% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2013-09-30 was $554.00.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2013 was $554.00.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2011 was $3.67K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|---|
| 2014-06-30 | $371.33K 10-Q · filed 2014-08-12 | $3.17M derived: sum of 2 quarters · filed 2014-08-12 | $3.61M 10-Q · filed 2014-08-12 | $3.49M derived: sum of 4 quarters · filed 2014-08-12 | |
| 2014-03-31 | $2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-06 | $3.12M 10-Q · filed 2014-05-06 | $3.12M derived: sum of 3 quarters · filed 2014-05-06 | $3.12M derived: sum of 4 quarters · filed 2014-08-12 | |
| 2013-12-31 | $314.86K 10-Q · filed 2014-02-04 | $315.41K derived: sum of 2 quarters · filed 2014-02-04 | $315.41K derived: sum of 3 quarters · filed 2014-08-12 | $314.86K derived: sum of 4 quarters · filed 2014-08-12 | |
| 2013-09-30 | $554.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-18 | $554.00 derived: sum of 2 quarters · filed 2014-08-12 | $0.00 derived: sum of 3 quarters · filed 2014-08-12 | $554.00 10-K · filed 2013-12-18 | |
| 2013-06-30 | $0.00 10-Q · filed 2014-08-12 | -$554.00 derived: sum of 2 quarters · filed 2014-08-12 | $0.00 10-Q · filed 2014-08-12 | $0.00 derived: sum of 4 quarters · filed 2014-08-12 | |
| 2013-03-31 | -$554.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-06 | $0.00 10-Q · filed 2014-05-06 | $0.00 derived: sum of 3 quarters · filed 2014-05-06 | $0.00 derived: sum of 4 quarters · filed 2014-05-06 | |
| 2012-12-31 | $554.00 10-Q · filed 2014-02-04 | $0.00 10-Q · filed 2013-02-13 | $554.00 derived: sum of 2 quarters · filed 2014-02-04 | $554.00 derived: sum of 3 quarters · filed 2014-02-04 | $554.00 derived: sum of 4 quarters · filed 2014-02-04 |
| 2012-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-18 | $0.00 derived: sum of 2 quarters · filed 2013-12-18 | $0.00 derived: sum of 3 quarters · filed 2013-12-18 | $0.00 10-K · filed 2013-12-18 | |
| 2012-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-08-13 | $0.00 derived: sum of 2 quarters · filed 2013-05-09 | $0.00 10-Q · filed 2012-08-13 | ||
| 2012-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-05-09 | $0.00 10-Q · filed 2013-05-09 | |||
| 2011-12-31 | $0.00 10-Q · filed 2013-02-13 | ||||
| 2011-09-30 | $3.67K 10-K · filed 2012-12-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |